AUS
NZ
UK
CA
USA
IND
Highlights
- PME share price rises over 11% in 2025 YTD
- Radiology software firm gains traction amid digital healthcare growth
- ASX200 stock showcases strong revenue momentum
Pro Medicus (ASX:PME) has emerged as one of the notable gainers on the ASX in 2025, with its share price climbing 11.6% year-to-date. As a key ASX200 stock, the company’s consistent performance is capturing attention in a volatile market landscape source.
A Glimpse into Pro Medicus’ Radiology Leadership
Pro Medicus is a global provider of advanced radiology IT solutions, delivering software that powers diagnostic imaging across hospitals, healthcare networks, and imaging centres. Its comprehensive suite encompasses Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation platforms.
Central to its innovation is the Visage software, a cloud-capable solution enabling radiologists to view and interpret large-scale medical images remotely — including on mobile devices. This capability allows medical professionals to make critical diagnostic decisions efficiently, contributing to improved patient care.
Healthcare's Resilience and Innovation
Healthcare has long been viewed as a resilient sector, often less susceptible to economic downturns. During challenging times, essential services like diagnostics and treatment remain in demand, giving companies like Pro Medicus a more stable revenue foundation.
In fact, historical data reveals that healthcare outperformed during major downturns such as the Global Financial Crisis. This “sticky” revenue — recurring and less cyclical — is one reason the sector remains attractive to long-term market participants.
Furthermore, the broader healthcare ecosystem is expanding rapidly. The U.S., which constitutes over 40% of global healthcare spending, is expected to grow its expenditure by 7% annually through 2027, potentially reaching USD 819 billion. Within this, digital health solutions — particularly those offering Software-as-a-Service (SaaS) — are forecast to grow revenue by more than 15% annually from 2024 to 2030.
Positioning for Sustainable Growth
As global interest in sustainable and ethical investing continues to rise, healthcare companies providing life-enhancing services are gaining favour. Sectors that align with public wellbeing are well-positioned to draw investment inflows, especially as market participants seek impact-oriented opportunities.
Valuation Snapshot
Currently, Pro Medicus trades at a price-to-sales ratio of 182.20x — a premium to its five-year average of 82.69x. This elevated ratio reflects robust revenue growth in recent years. While this valuation metric suggests strong investor confidence, it is important to consider a range of financial indicators when evaluating a company's long-term outlook.
Pro Medicus continues to attract attention through its innovative edge in radiology software, revenue momentum, and its place among the ASX200, positioning it as a noteworthy name in the evolving digital healthcare narrative.
